BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 18728104)

  • 1. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D; Gershenzon A; Corallo CE; Nagappan R
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
    Nykamp DL; Blackmon CL; Schmidt PE; Roberson AG
    Ann Pharmacother; 2005 Mar; 39(3):543-6. PubMed ID: 15687478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk-benefit profile of sibutramine.
    Scheen AJ
    Am J Cardiovasc Drugs; 2010; 10(5):321-34. PubMed ID: 20860415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT interval prolongation associated with sibutramine treatment.
    Harrison-Woolrych M; Clark DW; Hill GR; Rees MI; Skinner JR
    Br J Clin Pharmacol; 2006 Apr; 61(4):464-9. PubMed ID: 16542208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged QT interval, syncope, and delirium with galantamine.
    Fisher AA; Davis MW
    Ann Pharmacother; 2008 Feb; 42(2):278-83. PubMed ID: 18182475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sibutramine-induced acute myocardial infarction in a young lady.
    Yim KM; Ng HW; Chan CK; Yip G; Lau FL
    Clin Toxicol (Phila); 2008 Nov; 46(9):877-9. PubMed ID: 18788006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac arrest with pulseless electrical activity associated with methylphenidate in an adolescent with a normal baseline echocardiogram.
    Daly MW; Custer G; McLeay PD
    Pharmacotherapy; 2008 Nov; 28(11):1408-12. PubMed ID: 18957001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of QT dispersion after obesity drug sibutramine.
    Yalcin AA; Yavuz B; Ertugrul DT; Algul B; Yilmaz H; Deveci OS; Kucukazman M; Ata N; Demirel G; Dal K; Tutal E
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):832-5. PubMed ID: 20671571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sibutramine-associated psychosis (case report).
    Gazdag G; Szabó Z
    Neuropsychopharmacol Hung; 2008 May; 10(2):107-10. PubMed ID: 18959143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cesium-induced QT-interval prolongation in an adolescent.
    O'Brien CE; Harik N; James LP; Seib PM; Stowe CD
    Pharmacotherapy; 2008 Aug; 28(8):1059-65. PubMed ID: 18657021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: a pilot study.
    Ng TM; Bell AM; Hong C; Hara JM; Touchette DR; Danskey KN; Lindsay TT; Puumala SE
    Ann Pharmacother; 2008 Apr; 42(4):475-82. PubMed ID: 18319393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and prognostic significance of QT prolongation in chronic renal failure patients.
    Voiculescu M; Ionescu C; Ismail G
    Rom J Intern Med; 2006; 44(4):407-17. PubMed ID: 18386617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study.
    Mumford JL; Wu K; Xia Y; Kwok R; Yang Z; Foster J; Sanders WE
    Environ Health Perspect; 2007 May; 115(5):690-4. PubMed ID: 17520054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe symptomatic hyponatremia during sibutramine therapy: a case report.
    Esposito P; Rampino T; Gregorini M; Soccio G; Piotti G; Bedino G; Balenzano CT; Roscini E; Cosmai L; Portalupi V; Libetta C; Dal Canton A
    Am J Kidney Dis; 2008 Jul; 52(1):137-9. PubMed ID: 18487000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychotropic drugs associated with corrected QT interval prolongation.
    van Noord C; Straus SM; Sturkenboom MC; Hofman A; Aarnoudse AJ; Bagnardi V; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
    J Clin Psychopharmacol; 2009 Feb; 29(1):9-15. PubMed ID: 19142100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome.
    Batra AS; Silka MJ
    J Pediatr; 2002 Aug; 141(2):283-4. PubMed ID: 12183730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exertion syncopal crisis in the young, associated with idiopathic long QT syndrome].
    Mesquita A; Almeida M; Adragão P; Neves J; Morgado F; Parreira L; Nascimento R; Araújo JJ; Mendes M; Bonhorst D; Martins M; Seabra-Gomes R
    Rev Port Cardiol; 1996 Jan; 15(1):45-55. PubMed ID: 8703503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.